EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy
Purpose Approximately 80 % of patients with prostate cancer will develop bone metastases, which often lead to bone pain and skeletal-related events. Sr-89 is an established alternative for the palliation of bone pain in prostate cancer. We aimed to assess the effect of Sr-89 radionuclide therapy on...
Gespeichert in:
| Veröffentlicht in: | Annals of nuclear medicine 2012-07, Vol.26 (6), p.485-491 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 491 |
|---|---|
| container_issue | 6 |
| container_start_page | 485 |
| container_title | Annals of nuclear medicine |
| container_volume | 26 |
| creator | Kurosaka, Shinji Satoh, Takefumi Chow, Edward Asano, Yuji Tabata, Ken-ichi Kimura, Masaki Tsumura, Hideyasu Matsumoto, Kazumasa Ishiyama, Hiromichi Inoue, Yusuke Hayakawa, Kazushige Baba, Shiro |
| description | Purpose
Approximately 80 % of patients with prostate cancer will develop bone metastases, which often lead to bone pain and skeletal-related events. Sr-89 is an established alternative for the palliation of bone pain in prostate cancer. We aimed to assess the effect of Sr-89 radionuclide therapy on quality of life (QOL) in prostate cancer patients with painful bone metastases.
Materials and methods
Thirteen patients received a single intravenous injection of Sr-89 at a dose of 2.0 MBq/kg. All patients underwent QOL evaluation prior to Sr-89 treatment and 1, 2, and 3 months afterward using the Japanese version of the EORTC QLQ-BM22, EORTC QLQ-C30, a VAS, and face scale. We also evaluated PSA and ALP response and toxicity of the Sr-89 therapy.
Results
The pain characteristics subscale of the EORTC QLQ-BM22 was significantly reduced from 1 month onward compared with the baseline. The functional interference and psychosocial aspects subscales were significantly higher than baseline from 2 months onward. At 2 months, VAS indicated a significant reduction in pain as compared to the baseline. Sr-89 therapy caused a nonsignificant reduction in PSA and ALP levels. No patients had leukocyte toxicity, and one patient had grade 3 platelet toxicity.
Conclusion
Sr-89 radionuclide therapy can provide not only reduced pain characteristics but also better psychosocial aspects and functional interference in patients with painful bone metastases of prostate cancer. |
| doi_str_mv | 10.1007/s12149-012-0598-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1032891013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2714488041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c458t-c3fe662bfd907b82fbc728a0ef9dec311bd587ceb4c4772d84bfa504dde283fd3</originalsourceid><addsrcrecordid>eNqNkd9qFDEUxoModrv6AN5IwBtvovk3k8ylLtUKK6VSr4dMcmJTZjPbJEPZPosPa9apIoIghISP_L5zcvIh9ILRN4xS9TYzzmRHKOOENp0m94_QiulWklYK8RitaMckUUyrE3Sa8w2lXDeaP0UnnEuleCtW6PvZxZerDb7cXpL3nznHJrqfYiMovp3NGMoBTx6PwQPOdkqQcYh4b0qAWDK-C-W6qhD9POJhioB3UEyuq4LVt09TFQWwNdFCwiVBVW7x5ZKmWMK8I7rDybgwxdmOwQEu15DM_vAMPfFmzPD84Vyjrx_OrjbnZHvx8dPm3ZZY2ehCrPDQtnzwrqNq0NwPVnFtKPjOgRWMDa7RysIg7XFsp-XgTUOlc8C18E6s0eulbn3u7Qy59LuQLYyjiTDNuWdUcN0xysR_oFwJxXnd1-jVX-jNNKdYBzlSrZYd7XSl2ELZ-lU5ge_3KexMOlSoP6bcLyn3NeX-mHJ_Xz0vHyrPww7cb8evWCvAFyDXq_gN0p-t_1X1Bw2fs6E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1026849098</pqid></control><display><type>article</type><title>EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Kurosaka, Shinji ; Satoh, Takefumi ; Chow, Edward ; Asano, Yuji ; Tabata, Ken-ichi ; Kimura, Masaki ; Tsumura, Hideyasu ; Matsumoto, Kazumasa ; Ishiyama, Hiromichi ; Inoue, Yusuke ; Hayakawa, Kazushige ; Baba, Shiro</creator><creatorcontrib>Kurosaka, Shinji ; Satoh, Takefumi ; Chow, Edward ; Asano, Yuji ; Tabata, Ken-ichi ; Kimura, Masaki ; Tsumura, Hideyasu ; Matsumoto, Kazumasa ; Ishiyama, Hiromichi ; Inoue, Yusuke ; Hayakawa, Kazushige ; Baba, Shiro</creatorcontrib><description>Purpose
Approximately 80 % of patients with prostate cancer will develop bone metastases, which often lead to bone pain and skeletal-related events. Sr-89 is an established alternative for the palliation of bone pain in prostate cancer. We aimed to assess the effect of Sr-89 radionuclide therapy on quality of life (QOL) in prostate cancer patients with painful bone metastases.
Materials and methods
Thirteen patients received a single intravenous injection of Sr-89 at a dose of 2.0 MBq/kg. All patients underwent QOL evaluation prior to Sr-89 treatment and 1, 2, and 3 months afterward using the Japanese version of the EORTC QLQ-BM22, EORTC QLQ-C30, a VAS, and face scale. We also evaluated PSA and ALP response and toxicity of the Sr-89 therapy.
Results
The pain characteristics subscale of the EORTC QLQ-BM22 was significantly reduced from 1 month onward compared with the baseline. The functional interference and psychosocial aspects subscales were significantly higher than baseline from 2 months onward. At 2 months, VAS indicated a significant reduction in pain as compared to the baseline. Sr-89 therapy caused a nonsignificant reduction in PSA and ALP levels. No patients had leukocyte toxicity, and one patient had grade 3 platelet toxicity.
Conclusion
Sr-89 radionuclide therapy can provide not only reduced pain characteristics but also better psychosocial aspects and functional interference in patients with painful bone metastases of prostate cancer.</description><identifier>ISSN: 0914-7187</identifier><identifier>EISSN: 1864-6433</identifier><identifier>DOI: 10.1007/s12149-012-0598-z</identifier><identifier>PMID: 22477263</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Alkaline Phosphatase - blood ; Bone cancer ; Bone Neoplasms - blood ; Bone Neoplasms - complications ; Bone Neoplasms - radiotherapy ; Bone Neoplasms - secondary ; Humans ; Imaging ; Intravenous administration ; Leukocytes ; Male ; Medicine ; Medicine & Public Health ; Metastases ; Nuclear Medicine ; Original Article ; Pain ; Pain - complications ; Pain - radiotherapy ; Palliation ; Platelets ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - pathology ; Quality of Life ; Radioisotopes ; Radiology ; Strontium ; Strontium Radioisotopes - therapeutic use ; Toxicity</subject><ispartof>Annals of nuclear medicine, 2012-07, Vol.26 (6), p.485-491</ispartof><rights>The Japanese Society of Nuclear Medicine 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c458t-c3fe662bfd907b82fbc728a0ef9dec311bd587ceb4c4772d84bfa504dde283fd3</citedby><cites>FETCH-LOGICAL-c458t-c3fe662bfd907b82fbc728a0ef9dec311bd587ceb4c4772d84bfa504dde283fd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12149-012-0598-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12149-012-0598-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22477263$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kurosaka, Shinji</creatorcontrib><creatorcontrib>Satoh, Takefumi</creatorcontrib><creatorcontrib>Chow, Edward</creatorcontrib><creatorcontrib>Asano, Yuji</creatorcontrib><creatorcontrib>Tabata, Ken-ichi</creatorcontrib><creatorcontrib>Kimura, Masaki</creatorcontrib><creatorcontrib>Tsumura, Hideyasu</creatorcontrib><creatorcontrib>Matsumoto, Kazumasa</creatorcontrib><creatorcontrib>Ishiyama, Hiromichi</creatorcontrib><creatorcontrib>Inoue, Yusuke</creatorcontrib><creatorcontrib>Hayakawa, Kazushige</creatorcontrib><creatorcontrib>Baba, Shiro</creatorcontrib><title>EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy</title><title>Annals of nuclear medicine</title><addtitle>Ann Nucl Med</addtitle><addtitle>Ann Nucl Med</addtitle><description>Purpose
Approximately 80 % of patients with prostate cancer will develop bone metastases, which often lead to bone pain and skeletal-related events. Sr-89 is an established alternative for the palliation of bone pain in prostate cancer. We aimed to assess the effect of Sr-89 radionuclide therapy on quality of life (QOL) in prostate cancer patients with painful bone metastases.
Materials and methods
Thirteen patients received a single intravenous injection of Sr-89 at a dose of 2.0 MBq/kg. All patients underwent QOL evaluation prior to Sr-89 treatment and 1, 2, and 3 months afterward using the Japanese version of the EORTC QLQ-BM22, EORTC QLQ-C30, a VAS, and face scale. We also evaluated PSA and ALP response and toxicity of the Sr-89 therapy.
Results
The pain characteristics subscale of the EORTC QLQ-BM22 was significantly reduced from 1 month onward compared with the baseline. The functional interference and psychosocial aspects subscales were significantly higher than baseline from 2 months onward. At 2 months, VAS indicated a significant reduction in pain as compared to the baseline. Sr-89 therapy caused a nonsignificant reduction in PSA and ALP levels. No patients had leukocyte toxicity, and one patient had grade 3 platelet toxicity.
Conclusion
Sr-89 radionuclide therapy can provide not only reduced pain characteristics but also better psychosocial aspects and functional interference in patients with painful bone metastases of prostate cancer.</description><subject>Alkaline Phosphatase - blood</subject><subject>Bone cancer</subject><subject>Bone Neoplasms - blood</subject><subject>Bone Neoplasms - complications</subject><subject>Bone Neoplasms - radiotherapy</subject><subject>Bone Neoplasms - secondary</subject><subject>Humans</subject><subject>Imaging</subject><subject>Intravenous administration</subject><subject>Leukocytes</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Nuclear Medicine</subject><subject>Original Article</subject><subject>Pain</subject><subject>Pain - complications</subject><subject>Pain - radiotherapy</subject><subject>Palliation</subject><subject>Platelets</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Quality of Life</subject><subject>Radioisotopes</subject><subject>Radiology</subject><subject>Strontium</subject><subject>Strontium Radioisotopes - therapeutic use</subject><subject>Toxicity</subject><issn>0914-7187</issn><issn>1864-6433</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkd9qFDEUxoModrv6AN5IwBtvovk3k8ylLtUKK6VSr4dMcmJTZjPbJEPZPosPa9apIoIghISP_L5zcvIh9ILRN4xS9TYzzmRHKOOENp0m94_QiulWklYK8RitaMckUUyrE3Sa8w2lXDeaP0UnnEuleCtW6PvZxZerDb7cXpL3nznHJrqfYiMovp3NGMoBTx6PwQPOdkqQcYh4b0qAWDK-C-W6qhD9POJhioB3UEyuq4LVt09TFQWwNdFCwiVBVW7x5ZKmWMK8I7rDybgwxdmOwQEu15DM_vAMPfFmzPD84Vyjrx_OrjbnZHvx8dPm3ZZY2ehCrPDQtnzwrqNq0NwPVnFtKPjOgRWMDa7RysIg7XFsp-XgTUOlc8C18E6s0eulbn3u7Qy59LuQLYyjiTDNuWdUcN0xysR_oFwJxXnd1-jVX-jNNKdYBzlSrZYd7XSl2ELZ-lU5ge_3KexMOlSoP6bcLyn3NeX-mHJ_Xz0vHyrPww7cb8evWCvAFyDXq_gN0p-t_1X1Bw2fs6E</recordid><startdate>20120701</startdate><enddate>20120701</enddate><creator>Kurosaka, Shinji</creator><creator>Satoh, Takefumi</creator><creator>Chow, Edward</creator><creator>Asano, Yuji</creator><creator>Tabata, Ken-ichi</creator><creator>Kimura, Masaki</creator><creator>Tsumura, Hideyasu</creator><creator>Matsumoto, Kazumasa</creator><creator>Ishiyama, Hiromichi</creator><creator>Inoue, Yusuke</creator><creator>Hayakawa, Kazushige</creator><creator>Baba, Shiro</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20120701</creationdate><title>EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy</title><author>Kurosaka, Shinji ; Satoh, Takefumi ; Chow, Edward ; Asano, Yuji ; Tabata, Ken-ichi ; Kimura, Masaki ; Tsumura, Hideyasu ; Matsumoto, Kazumasa ; Ishiyama, Hiromichi ; Inoue, Yusuke ; Hayakawa, Kazushige ; Baba, Shiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c458t-c3fe662bfd907b82fbc728a0ef9dec311bd587ceb4c4772d84bfa504dde283fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Alkaline Phosphatase - blood</topic><topic>Bone cancer</topic><topic>Bone Neoplasms - blood</topic><topic>Bone Neoplasms - complications</topic><topic>Bone Neoplasms - radiotherapy</topic><topic>Bone Neoplasms - secondary</topic><topic>Humans</topic><topic>Imaging</topic><topic>Intravenous administration</topic><topic>Leukocytes</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Nuclear Medicine</topic><topic>Original Article</topic><topic>Pain</topic><topic>Pain - complications</topic><topic>Pain - radiotherapy</topic><topic>Palliation</topic><topic>Platelets</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Quality of Life</topic><topic>Radioisotopes</topic><topic>Radiology</topic><topic>Strontium</topic><topic>Strontium Radioisotopes - therapeutic use</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kurosaka, Shinji</creatorcontrib><creatorcontrib>Satoh, Takefumi</creatorcontrib><creatorcontrib>Chow, Edward</creatorcontrib><creatorcontrib>Asano, Yuji</creatorcontrib><creatorcontrib>Tabata, Ken-ichi</creatorcontrib><creatorcontrib>Kimura, Masaki</creatorcontrib><creatorcontrib>Tsumura, Hideyasu</creatorcontrib><creatorcontrib>Matsumoto, Kazumasa</creatorcontrib><creatorcontrib>Ishiyama, Hiromichi</creatorcontrib><creatorcontrib>Inoue, Yusuke</creatorcontrib><creatorcontrib>Hayakawa, Kazushige</creatorcontrib><creatorcontrib>Baba, Shiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Annals of nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kurosaka, Shinji</au><au>Satoh, Takefumi</au><au>Chow, Edward</au><au>Asano, Yuji</au><au>Tabata, Ken-ichi</au><au>Kimura, Masaki</au><au>Tsumura, Hideyasu</au><au>Matsumoto, Kazumasa</au><au>Ishiyama, Hiromichi</au><au>Inoue, Yusuke</au><au>Hayakawa, Kazushige</au><au>Baba, Shiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy</atitle><jtitle>Annals of nuclear medicine</jtitle><stitle>Ann Nucl Med</stitle><addtitle>Ann Nucl Med</addtitle><date>2012-07-01</date><risdate>2012</risdate><volume>26</volume><issue>6</issue><spage>485</spage><epage>491</epage><pages>485-491</pages><issn>0914-7187</issn><eissn>1864-6433</eissn><abstract>Purpose
Approximately 80 % of patients with prostate cancer will develop bone metastases, which often lead to bone pain and skeletal-related events. Sr-89 is an established alternative for the palliation of bone pain in prostate cancer. We aimed to assess the effect of Sr-89 radionuclide therapy on quality of life (QOL) in prostate cancer patients with painful bone metastases.
Materials and methods
Thirteen patients received a single intravenous injection of Sr-89 at a dose of 2.0 MBq/kg. All patients underwent QOL evaluation prior to Sr-89 treatment and 1, 2, and 3 months afterward using the Japanese version of the EORTC QLQ-BM22, EORTC QLQ-C30, a VAS, and face scale. We also evaluated PSA and ALP response and toxicity of the Sr-89 therapy.
Results
The pain characteristics subscale of the EORTC QLQ-BM22 was significantly reduced from 1 month onward compared with the baseline. The functional interference and psychosocial aspects subscales were significantly higher than baseline from 2 months onward. At 2 months, VAS indicated a significant reduction in pain as compared to the baseline. Sr-89 therapy caused a nonsignificant reduction in PSA and ALP levels. No patients had leukocyte toxicity, and one patient had grade 3 platelet toxicity.
Conclusion
Sr-89 radionuclide therapy can provide not only reduced pain characteristics but also better psychosocial aspects and functional interference in patients with painful bone metastases of prostate cancer.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>22477263</pmid><doi>10.1007/s12149-012-0598-z</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0914-7187 |
| ispartof | Annals of nuclear medicine, 2012-07, Vol.26 (6), p.485-491 |
| issn | 0914-7187 1864-6433 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1032891013 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Alkaline Phosphatase - blood Bone cancer Bone Neoplasms - blood Bone Neoplasms - complications Bone Neoplasms - radiotherapy Bone Neoplasms - secondary Humans Imaging Intravenous administration Leukocytes Male Medicine Medicine & Public Health Metastases Nuclear Medicine Original Article Pain Pain - complications Pain - radiotherapy Palliation Platelets Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - pathology Quality of Life Radioisotopes Radiology Strontium Strontium Radioisotopes - therapeutic use Toxicity |
| title | EORTC QLQ-BM22 and QLQ-C30 quality of life scores in patients with painful bone metastases of prostate cancer treated with strontium-89 radionuclide therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T11%3A08%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EORTC%20QLQ-BM22%20and%20QLQ-C30%20quality%20of%20life%20scores%20in%20patients%20with%20painful%20bone%20metastases%20of%20prostate%20cancer%20treated%20with%20strontium-89%20radionuclide%20therapy&rft.jtitle=Annals%20of%20nuclear%20medicine&rft.au=Kurosaka,%20Shinji&rft.date=2012-07-01&rft.volume=26&rft.issue=6&rft.spage=485&rft.epage=491&rft.pages=485-491&rft.issn=0914-7187&rft.eissn=1864-6433&rft_id=info:doi/10.1007/s12149-012-0598-z&rft_dat=%3Cproquest_cross%3E2714488041%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1026849098&rft_id=info:pmid/22477263&rfr_iscdi=true |